Asking Price Contact for pricing
NOI Net Operating Income N/A
Cap Rate N/A
Asking Price Contact for pricing
NOI Net Operating Income N/A
Cap Rate N/A

Documents

Enter the "Deal room" for exclusive documents related to this property.

The Deal Room features confidential documents related to this property. To access the Deal Room, you will need to be logged in. If you don't have an account, please create one. More questions? Visit our FAQ.
I accept the confidentiality agreement
Create an account on the Investor Center to save your search and investment preferences, save and share opportunities, access exclusive documents, and more. More questions? Visit our FAQ. Approval for Deal Room access requires review by our Broker Team. You will be notified by email once your access is granted. More questions? Visit our FAQ. You'll need to sign a Confidentiality Agreement (CA) to access exclusive documents in the Deal Room. Signing the CA means you agree not to divulge or release sensitive information related to this property. More questions? Visit our FAQ.
I accept the confidentiality agreement I accept the confidentiality agreement
Create an account on the Investor Center to save your search and investment preferences, save and share opportunities, access exclusive documents, and more. More questions? Visit our FAQ. You'll need to sign a Confidentiality Agreement (CA) to access exclusive documents in the Deal Room. Signing the CA means you agree not to divulge or release sensitive information related to this property. More questions? Visit our FAQ.

Key Facts

Year Built 2016
Building Area

Property Description

Jones Lang LaSalle Americas, Inc. ("JLL"), as exclusive representative for the Owner, is pleased to present this offering for the sale of US Pharmacopeia’s Frederick Life Science Production Facility (the "Property"), located at 7135 English Muffin Way in Frederick, Maryland. The 63,054 square foot mission critical asset is 100% leased to US Pharmacopeia under a triple net lease with 3% annual escalations and no termination nor contraction options through June 2031. US Pharmacopeia is a well-capitalized non-profit whose central role in the global pharmaceutical industry is enshrined by federal law. The Property is strategically located in Frederick, Maryland and serves as the US Pharmacopeia’s primary production facility globally.

 

Accordingly, USP Frederick presents investors with an outstanding opportunity to acquire a mission-critical life science facility with stable cash flow and attractive yields in an established and growing life science cluster.

Investment Highlights

  • 100% leased to US Pharmacopeia ("USP") through June 2031 with no termination nor contraction options
  • Triple net lease with 3% annual escalations
  • USP is a well-capitalized non-profit whose role in the global pharmaceutical industry is mandated by federal law
  • Mission critical & highly specialized life science facility that serves as tenant's primary production facility globally
  • Strategically located in Frederick, Maryland, a vibrant life science cluster with 0.4% total availability
  • In close proximity to Fort Detrick, which houses some of the US government’s most advanced biological research functions: National Interagency Biodefense Campus, National Biodefense Analysis and Countermeasures Center, the US Army Medical Research Institute of Infectious Diseases and the US Army Medical Research and Material Command Center, amongst many others
  • The National Cancer Institute, AstraZeneca, ThermoFisher Scientific, Charles River Laboratories, Lonza, and Qiagen all maintain a significant presence in the Frederick market
Last Updated Date: 10 May 2021
Jim Meisel
Jim Meisel
Senior Managing Director, Washington, D.C. Office Co-Head
Broker Licenses
DC-SP100478 MD-521313 VA-0225049461
David Baker
David Baker
Director, Capital Markets
Broker Licenses
DC-SP98379962 MD-645831 VA-0225228839

Please enter your corporate email account in the email field. We may not be able to reply to your personal email account or free email address such as Gmail or Yahoo Mail.

There was an error submitting your request. Please try again, or submit you inquiry here.

 

PRIVACY NOTICE

Jones Lang LaSalle (JLL), together with its subsidiaries and affiliates, is a leading global provider of real estate and investment management services. We take our responsibility to protect the personal information provided to us seriously.

Generally the personal information we collect from you are for the purposes of dealing with your enquiry.

We endeavor to keep your personal information secure with appropriate level of security and keep for as long as we need it for legitimate business or legal reasons. We will then delete it safely and securely. For more information about how JLL processes your personal data, please view our privacy statement.

Last Updated Date: 10 May 2021

Do you have any questions?  Visit our FAQ page

The value of trust beneficiary rights fluctuates due to fluctuations in the price of real estate, and there is a risk of falling beyond the investment principal. Real estate prices are fluctuated by changes in the population of the area in which they are located and the number of newly supplied properties, fluctuations in interest rates and exchange rates, changes of tax system, loss/damage due to natural disasters such as earthquakes, deterioration over time, and the discovery of hidden defects such as soil pollution.

Please go to the below link for our commitment to compliance (Japanese only).

https://www.joneslanglasalle.co.jp/ja/compliance-with-laws-and-regulations-and-its-representation

JLL  financing

JLL can help you finance and manage your portfolio.
Email us today to see how we can help achieve your ambitions.